Context: Published studies of thyroid stunning due to preablation 131I scanning in the
treatment of differentiated thyroid cancer after thyroidectomy had shown inconsistent clinical …

Context: Recent trial results have revived interest in low-activity initial 131I therapy (RIT) of
differentiated thyroid cancer (DTC). Objective: This study sought to compare different initial …

Summary objective To evaluate the risk of performing inappropriate 131I ablative therapies
for thyroid carcinoma in patients lacking thyroid remnants or metastases, using a strategy of …

Objectives Currently, little is known about the prognostic significance of achieving successful
ablation with the first dosage of I-131 in patients with differentiated thyroid cancer. This study …

Background In the management of patients with differentiated thyroid carcinoma, direct
comparison of the presence of scintigraphic stunning after a diagnostic dose of 131 I with …

Objective: Dosimetry studies have shown that activities of 131 I as small as 10-20 MBq may
cause a stunning effect. A result of this stunning effect may be a lower success rate of the …

Purpose To determine whether thyroid-stimulating hormone level≥ 30 mU/L is necessary
for radioiodine (131 I) remnant ablation (RRA) in patients with differentiated thyroid cancer …

Objective To investigate predictors for successful ablation and disease-free status after high-
dose radioiodine therapy in patients with differentiated thyroid cancer. Methods We enrolled …

Purpose This article examines the outcome of radioactive iodine ablation therapy for thyroid
cancer in high-risk patients and investigates background factors influencing ablation failure …

Purpose 131 I whole-body scan (WBS) and serum thyroglobulin (TG) are important in
detecting thyroid remnants or recurrent disease in patients with differentiated thyroid cancer …